BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37819451)

  • 1. Total-body PET/CT with half-dose [
    Liu Y; Li L; Qin Y; Chen Z; Zhao H; Wang X; Chen R
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):581-589. PubMed ID: 37819451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total-body [
    Wang Y; Chen Z; Zhu Y; Zhao H; Li L; Huang G; Xue W; Chen R; Liu J
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4096-4106. PubMed ID: 37578502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
    Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of uptake time on image quality of [
    van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
    Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection efficacy of [
    Rosar F; Khreish F; Marlowe RJ; Schaefer-Schuler A; Burgard C; Maus S; Petto S; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of [
    Wang G; Hong H; Zang J; Liu Q; Jiang Y; Fan X; Zhu Z; Zhu L; Kung HF
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1052-1062. PubMed ID: 34557930
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
    BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences.
    Alberts I; Prenosil G; Mingels C; Bohn KP; Viscione M; Sari H; Rominger A; Afshar-Oromieh A
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4456-4462. PubMed ID: 34155538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary Evaluation of
    Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA
    Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total-Body
    Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.